MOA Plazomicin exerts a bactericidal action against susceptible bacteria by binding to bacterial 30S ribosomal subunit [A33942]. Aminoglycosides typically bind to the ribosomal aminoacyl-tRNA site (A-site) and induce a conformational change to further facilitate the binding between the rRNA and the antibiotic [A15783]. This leads to codon misreading and mistranslation of mRNA during bacterial protein synthesis [A15783]. ; ; Plazomicin demonstrates potency against _Enterobacteriaceae_, including species with multidrug-resistant phenotypes such as carbapenemase-producing bacteria and isolates with resistance to all other aminoglycosides [A33942, A33943, A33944]. Its antibacterial activity is not inhibited by aminoglycoside modifying enzymes (AMEs) produced by bacteria, such as acetyltransferases (AACs), phosphotransferases (APHs), and nucleotidyltransferases (ANTs) [A33945, FDA Label]. Plazomicin was shown to be effective against _Enterobacteriaceae_ in presence of some beta-lactamases [FDA Label]. In clinical settings and _in vivo_, bacteria shown to be susceptible toward plazomicin include _Escherichia_ _coli_, _Klebsiella pneumoniae_, _Proteus mirabilis_, and _Enterobacter cloacae_ [FDA Label]. Other aerobic bacteria that may be affected by plazomicin are _Citrobacter freundii_, _Citrobacter koseri_, _Enterobacter aerogenes_, _Klebsiella oxytoca_, _Morganella morganii_, _Proteus vulgaris_, _Providencia stuartii_, and _Serratia marcescens_ [FDA Label].

DESCRIPTION Plazomicin is a semisynthetic derivative of and belongs to the aminoglycoside class of antibacterial compounds . (GtoPdb)